India covid-19 testing infection patient growth India

Glenmark’s Fabiflu is first in the market, but has limited growth opportunity

Reading now: 592
www.livemint.com

₹103 per tablet, while Glenmark has the first-mover advantage. But the revenue potential of the drug depends on the infection rate and the adoption of the drug as a treatment."This appears to be a one time opportunity only for covid times.

Multiple players are set to launch the product over the next 12 months given that there are no patents in India," said Anshuman Gupta, pharma analyst, Investec Securities.As such, the revenue potential is expected to decrease once competition kicks in.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA